Medline CEO James M Boyle Gets 2,516,260 Voting Shares With No Economic Value
The compensation conversions account for about 82% of Boyle's reported post-transaction shares, including holdings in a family trust.
James M Boyle, CEO of Medline, which makes and distributes medical-surgical supplies, received 2,516,260 voting shares Thursday through compensation conversions, according to an SEC filing filed Monday. The Class B shares each provide a vote but have no economic value themselves; the economic interests sit in accompanying Medline Holdings units.
Votes Paired With Ownership Units
The grants account for about 82% of Boyle's 3,055,449 reported post-transaction shares. He holds 1,869,921 directly, with another 1,185,528 held by a family trust whose trustee is his spouse.
Medline issues a Class B share alongside each common unit in Medline Holdings, the entity whose units can be exchanged for publicly traded Class A stock. Each common unit can be exchanged for one Class A share, and the matching Class B share is canceled automatically when that happens. The exchange rights have no expiration.
Appreciation Awards Become Common Units
Boyle converted 4,052,948 incentive units and reported exercises involving 4,052,948 common units. Another 1,536,688 common units were withheld for taxes in the transaction.
The incentive awards give holders an economic interest in appreciation above a specified participation threshold. Holders can choose to convert vested awards into common units, with the calculation using Medline's publicly traded share price and the applicable threshold. The incentive units do not expire.
The exchange framework dates to December 16, 2025. Incentive and common units are held through Medline Management Aggregator, the entity used to hold those interests.
More Awards Vest In 2027
The remaining incentive awards follow different vesting schedules. Two groups are 60% vested, with the remaining 40% due in two equal annual installments starting April 1 and October 1, 2027, respectively.
Another group is 40% vested, with the rest scheduled for three equal annual installments beginning March 29, 2027. A group that is 20% vested has its remaining 80% scheduled to vest in four equal annual installments beginning March 28, 2027.
Medline supplies hospitals, surgery centers, physician offices and post-acute facilities. Its Medline Brand segment sells its own products, while Supply Chain Solutions distributes other suppliers' products and provides warehouse and logistics services.
For Boyle, exchanging the common units into Class A stock also removes the corresponding Class B votes.
Sources
- Form 4 — James M Boyle (MDLN) — SEC EDGAR